Forest antidepressant Viibryd succeeds in anxiety disorder trials
June 23 (Reuters) - Forest Laboratories Inc, which is being acquired by generic drugmaker Actavis Plc, said on Monday that its antidepressant Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, according to data from three late-stage studies.
Forest announced the top line results from three Phase III studies involving a total of nearly 1,500 patients suffering from generalized anxiety disorder (GAD) - two flexible-dose studies and one fixed-dose trial.
In each study, the company said, Viibryd proved statistically significantly better in lowering scores on the Hamilton Rating Scale for Anxiety compared with patients who received a placebo. Forest did not release detailed results.
Viibryd, known chemically as vilazodone, had sales of $52.8 million in the most recent quarter for treatment of major depressive disorder. An expanded approval for GAD should help increase sales of the medicine.
Forest said it expected to file its supplemental application seeking U.S. approval for Viibryd in GAD in 2015.
- Tesla prevails in top Massachusetts court over direct sales
- Obama to deploy 3,000 troops as Eboola crisis worsens
- World stocks hit one-month low, caution ahead of Fed
- Russia needs government investment to avoid recession, says former finance minister
- Ahead of independence vote, Britain pledges state funding to Scotland